Depomed Q3 top line up 104%; net income down 283%; guidance raised; shares up 5%

• Depomed (DEPO) Q3 results ($M): Total Revenues: 104.9 (+103.7%); Nucynta: 64.9; Gralise: 21.1 (+29.4%); Cambia: 7.1 (+21.0%); Lazanda: 5.4 (+134.8%); Zipsor: 6.2 (+0.5%).
• Net Loss: (11.8) (-282.6%); Loss Per Share: (0.20) (-281.8%); Quick Assets: 174.5 (-69.2%).
• 2015 Guidance: Product Sales: $336M - 348M from $320M - 340M; Non-GAAP EBITDA: $108M - 116M from $95M - 110M; Non-GAAP Net Income: $58M - 66M from $40M - 50M.
• Shares are up 5% after hours on increased volume.